Although anaplastic lymphoma kinase (ALK)–tyrosine kinase inhibitors (TKIs) have been approved for the treatment of locally advanced non-small cell lung cancer (NSCLC) caused by ALK rearrangement [1], its treatment after failure of initial ALK–TKI therapy remains controversial. This evidence concerns the gene ALK and non-small cell lung carcinoma.